Kelly Lawrence W & Associates’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $203K | Hold |
263
| – | – | 0.06% | 81 |
|
|
2025
Q4 | $203K | Hold |
263
| – | – | 0.05% | 83 |
|
|
2025
Q3 | $148K | Hold |
263
| – | – | 0.04% | 93 |
|
|
2025
Q2 | $138K | Hold |
263
| – | – | 0.04% | 89 |
|
|
2025
Q1 | $167K | Hold |
263
| – | – | 0.04% | 88 |
|
|
2024
Q4 | $187K | Buy |
263
+25
| +11% | +$21K | 0.04% | 86 |
|
|
2024
Q3 | $250K | Hold |
238
| – | – | 0.06% | 77 |
|
|
2024
Q2 | $250K | Buy |
238
+4
| +2% | +$3.88K | 0.06% | 74 |
|
|
2024
Q1 | $225K | Sell |
234
-6
| -3% | -$5.71K | 0.05% | 70 |
|
|
2023
Q4 | $211K | Hold |
240
| – | – | 0.05% | 75 |
|
|
2023
Q3 | $198K | Sell |
240
-125
| -34% | -$98.2K | 0.05% | 73 |
|
|
2023
Q2 | $285K | Sell |
365
-20
| -5% | -$15.4K | 0.07% | 67 |
|
|
2023
Q1 | $316K | Hold |
385
| – | – | 0.09% | 65 |
|
|
2022
Q4 | $278K | Hold |
385
| – | – | 0.08% | 66 |
|
|
2022
Q3 | $265K | Hold |
385
| – | – | 0.07% | 76 |
|
|
2022
Q2 | $228K | Hold |
385
| – | – | 0.06% | 78 |
|
|
2022
Q1 | $269K | Hold |
385
| – | – | 0.06% | 69 |
|
|
2021
Q4 | $243K | Hold |
385
| – | – | 0.05% | 72 |
|
|
2021
Q3 | $233K | Hold |
385
| – | – | 0.05% | 73 |
|
|
2021
Q2 | $215K | Hold |
385
| – | – | 0.05% | 76 |
|
|
2021
Q1 | $182K | Buy |
385
+34
| +10% | +$16.6K | 0.04% | 73 |
|
|
2020
Q4 | $170K | Sell |
351
-845
| -71% | -$456K | 0.07% | 53 |
|
|
2020
Q3 | $669K | Buy |
1,196
+20
| +2% | +$12.1K | 0.2% | 44 |
|
|
2020
Q2 | $733K | Sell |
1,176
-325
| -22% | -$184K | 0.15% | 42 |
|
|
2020
Q1 | $733K | Sell |
1,501
-2,950
| -66% | -$1.22M | 0.18% | 44 |
|
|
2019
Q4 | $1.67M | Hold |
4,451
| – | – | 0.26% | 39 |
|
|
2019
Q3 | $1.24M | Buy |
4,451
+335
| +8% | +$99.1K | 0.21% | 43 |
|
|
2019
Q2 | $1.29M | Sell |
4,116
-185
| -4% | -$61.6K | 0.22% | 43 |
|
|
2019
Q1 | $1.77M | Sell |
4,301
-1,410
| -25% | -$581K | 0.32% | 39 |
|
|
2018
Q4 | $2.13M | Sell |
5,711
-19,949
| -78% | -$7.3M | 0.46% | 36 |
|
|
2018
Q3 | $10.4M | Buy |
25,660
+435
| +2% | +$166K | 1.71% | 27 |
|
|
2018
Q2 | $8.7M | Buy |
25,225
+300
| +1% | +$93.8K | 1.6% | 27 |
|
|
2018
Q1 | $8.58M | Sell |
24,925
-340
| -1% | -$118K | 1.63% | 26 |
|
|
2017
Q4 | $9.5M | Hold |
25,265
| – | – | 1.75% | 23 |
|
|
2017
Q3 | $11.3M | Buy |
25,265
+45
| +0.2% | +$21.4K | 2.15% | 23 |
|
|
2017
Q2 | $12.4M | Buy |
25,220
+680
| +3% | +$298K | 2.45% | 20 |
|
|
2017
Q1 | $9.51M | Buy |
24,540
+24,390
| +16,260% | +$9.04M | 1.96% | 24 |
|
|
2016
Q4 | $55K | Hold |
150
| – | – | 0.01% | 123 |
|
|
2016
Q3 | $60K | Hold |
150
| – | – | 0.01% | 126 |
|
|
2016
Q2 | $52K | Buy |
+150
| New | +$57.8K | 0.01% | 135 |
|
Other funds holding REGN
VCM
N
Kelly Lawrence W & Associates's REGN Position: Q1 2026 in Review
Kelly Lawrence W & Associates held its Regeneron Pharmaceuticals (REGN) position steady in Q1 2026 at 263 shares worth $203K. The position accounts for 0.06% of the portfolio, ranked #81.
Kelly Lawrence W & Associates first reported a position in REGN in Q2 2016 and has held it in 40 quarters since. The position peaked at $12.4M in Q2 2017. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Kelly Lawrence W & Associates held 263 shares of Regeneron Pharmaceuticals worth $203K as of Q1 2026.
- Kelly Lawrence W & Associates left its Regeneron Pharmaceuticals share count unchanged in Q1 2026.
- Regeneron Pharmaceuticals made up 0.06% of Kelly Lawrence W & Associates's portfolio in Q1 2026, its #81 holding.
- Kelly Lawrence W & Associates first reported a position in Regeneron Pharmaceuticals in Q2 2016 and has held it in 40 quarters since.
- Kelly Lawrence W & Associates's Regeneron Pharmaceuticals position peaked at $12.4M in Q2 2017.
- 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Kelly Lawrence W & Associates's 13F filing for Q1 2026, filed 15 May 2026.